The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I, dose-escalation, multi-center study of PFK-158 in patients with advanced solid malignancies explores a first-in-man inhbibitor of glycolysis.
 
Rebecca A. Redman
No Relationships to Disclose
 
Paula Raffin Pohlmann
Stock and Other Ownership Interests - Immunonet BioSciences
Consulting or Advisory Role - Personalized Cancer Therapy
Patents, Royalties, Other Intellectual Property - IMMUNOLOGICAL COMPOSITIONS AS CANCER BIOMARKERS AND/OR THERAPEUTICS; U.S. Patent and Trademark Office No. US 20120201820. Invention title: Immunological Compositions as Cancer Therapeutics.
 
Michael R. Kurman
Consulting or Advisory Role - Advanced Cancer Therapeutics
 
Gilles Tapolsky
Employment - Advanced Cancer Therapeutics
Leadership - Advanced Cancer Therapeutics
Stock and Other Ownership Interests - Advanced Cancer Therapeutics
Patents, Royalties, Other Intellectual Property - Tapestry Pharmaceuticals
 
Jason Alan Chesney
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb
Research Funding - Amgen; Angimmune; BioVex; Bristol-Myers Squibb; Eisai; Genentech